SINTX Technologies Inc is a biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years' experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications.
Last trade$1.20
Day change-$0.14 (-10.45%)
Day range$1.19 – $1.60
Volume48,192
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.13M
Price / earnings
—
Price / book
2.99×
Price / sales
3.06×
EV / sales
2.47×
EV / EBITDA
-0.84×
Profitability
Earnings per share
-$1.36
Return on assets
-115.28%
Return on equity
-302.74%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.02×
Current ratio
1.84×
Quick ratio
0.99×
Cash ratio
0.67×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.25M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SINT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.19M
$452K
$380K
$290K
$208K
$151K
$369K
$542K
Cost of revenue
$828K
$174K
$236K
$102K
$115K
$94K
$246K
$154K
Gross profit
$1.36M
$278K
$144K
$188K
$93K
$57K
$123K
$388K
Selling, general and administrative
$2.39M
$2.59M
$2.93M
$1.5M
$2.16M
$1.44M
$1.34M
$1.03M
Research and development
$548K
$573K
$364K
$969K
$1.26M
$1.24M
$1.12M
$709K
Total operating expenses
$3M
$3.17M
$3.35M
$2.51M
$3.45M
$2.72M
$2.51M
$2.12M
Operating income
-$1.64M
-$2.89M
-$3.21M
-$2.32M
-$3.36M
-$2.67M
-$2.38M
-$1.73M
Interest expense
-$2K
-$2K
-$12K
-$12K
-$13K
-$14K
-$13K
-$14K
Income before taxes
-$1.6M
-$2.71M
-$2.82M
-$2.22M
-$3.54M
-$2.32M
-$2.29M
-$1.7M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.6M
-$2.71M
-$2.82M
-$2.22M
-$3.54M
-$2.32M
-$2.29M
-$1.7M
Net income attributable to common shareholders
-$1.6M
-$3.63M
-$2.82M
-$2.22M
-$10.26M
-$2.32M
-$2.29M
-$1.7M
EBITDA
-$1.57M
-$2.82M
-$3.13M
-$2.24M
-$3.27M
-$2.59M
-$2.29M
-$1.62M
Basic earnings per share
-$0.24
-$0.75
-$0.70
-$0.58
-$3.46
-$0.91
-$1.29
-$1.25
Diluted earnings per share
-$0.24
-$0.75
-$0.70
-$0.58
-$3.46
-$0.91
-$1.29
-$1.40
Recent news
Company coverage with links to the original publishers.
SINTX Technologies has completed its advanced 3D printing facility buildout and received medical-grade additive manufacturing systems. The company is advancing its proprietary silicon nitride-PEEK composite technology for personalized orthopedic implants, with plans to pursue FDA 510(k) clearance and target initial product availability in 2027. The company also appointed a new Director of 3D Additive-Manufacturing and is exploring partnerships for AI-assisted surgical planning and international commercialization.
SINTX Technologies received a Zacks Rank #2 (Buy) upgrade driven by upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 has increased 26.4% over the past three months, positioning it in the top 20% of Zacks-covered stocks and suggesting potential near-term stock price appreciation.
SINTX Technologies has engaged Southern Metrics Consulting, led by veteran MedTech executive Chris Lyons (who serves on SINTX's Board since April 2025), to establish a Strategic Opportunity Management Program. The program will identify and evaluate strategic opportunities including partnerships, licensing, investments, joint ventures, and acquisitions to enhance stockholder value as the company transitions from development to commercial-stage operations.
SINTX Technologies announced its participation in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4-5, 2026. The company will present updates on its operational progress, silicon nitride biomaterial platform, regulatory milestones, and opportunities in orthopedic, spine, and patient-specific applications following recent operational restructuring and strategic refocus.
SINTX Technologies launched OsseoSculpt™, a next-generation biologic designed to complement its SINAPTIC® Foot & Ankle Osteotomy Wedge System. The company recorded its first commercial revenue in Q3 2025 and plans a broader U.S. rollout through Q4 2025–Q1 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.